Machina Capital S.A.S. Grows Position in Bristol Myers Squibb Company $BMY

Machina Capital S.A.S. raised its position in Bristol Myers Squibb Company (NYSE:BMY) by 92.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 111,926 shares of the biopharmaceutical company’s stock after buying an additional 53,890 shares during the quarter. Bristol Myers Squibb makes up approximately 0.9% of Machina Capital S.A.S.’s portfolio, making the stock its 21st biggest position. Machina Capital S.A.S.’s holdings in Bristol Myers Squibb were worth $5,048,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the business. Gateway Investment Advisers LLC grew its stake in Bristol Myers Squibb by 10.0% in the 3rd quarter. Gateway Investment Advisers LLC now owns 113,457 shares of the biopharmaceutical company’s stock valued at $5,117,000 after acquiring an additional 10,284 shares during the last quarter. CWA Asset Management Group LLC grew its position in shares of Bristol Myers Squibb by 25.9% in the third quarter. CWA Asset Management Group LLC now owns 150,359 shares of the biopharmaceutical company’s stock valued at $6,781,000 after purchasing an additional 30,909 shares during the last quarter. Commonwealth Retirement Investments LLC grew its position in shares of Bristol Myers Squibb by 24.6% in the second quarter. Commonwealth Retirement Investments LLC now owns 59,183 shares of the biopharmaceutical company’s stock valued at $2,740,000 after purchasing an additional 11,690 shares during the last quarter. Railway Pension Investments Ltd increased its stake in shares of Bristol Myers Squibb by 3.7% during the 3rd quarter. Railway Pension Investments Ltd now owns 1,139,600 shares of the biopharmaceutical company’s stock worth $51,396,000 after purchasing an additional 40,300 shares in the last quarter. Finally, Stephens Inc. AR lifted its stake in Bristol Myers Squibb by 13.5% in the 3rd quarter. Stephens Inc. AR now owns 273,343 shares of the biopharmaceutical company’s stock valued at $12,328,000 after buying an additional 32,476 shares in the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Bristol Myers Squibb Trading Up 0.1%

Shares of BMY stock opened at $55.97 on Wednesday. The firm’s 50-day simple moving average is $53.71 and its 200-day simple moving average is $48.78. The company has a debt-to-equity ratio of 2.39, a current ratio of 1.27 and a quick ratio of 1.17. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $63.33. The firm has a market cap of $113.94 billion, a P/E ratio of 18.91, a PEG ratio of 0.17 and a beta of 0.29.

Bristol Myers Squibb Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd were issued a $0.63 dividend. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. The ex-dividend date was Friday, January 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.5%. Bristol Myers Squibb’s dividend payout ratio (DPR) is 85.14%.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on BMY shares. Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. The Goldman Sachs Group reiterated a “neutral” rating and set a $57.00 price objective (up previously from $51.00) on shares of Bristol Myers Squibb in a research report on Tuesday, December 2nd. Morgan Stanley restated an “underweight” rating and issued a $37.00 target price (up from $36.00) on shares of Bristol Myers Squibb in a report on Friday, December 12th. Sanford C. Bernstein reiterated a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, November 3rd. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Bristol Myers Squibb in a research note on Tuesday, October 14th. Seven investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $57.43.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.